Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALTOTCMKTS:FSDDFNASDAQ:RAPPNASDAQ:TNGX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALTAltimmune$6.92-3.2%$5.28$3.55▼$11.16$561.26M0.582.88 million shs4.32 million shsFSDDFFSD Pharma$19.00+23.6%$9.49$3.43▼$68.66$144.02MN/A11,100 shs520,428 shsRAPPRapport Therapeutics$11.19+0.4%$10.51$6.43▼$29.74$408.41MN/A170,902 shs101,119 shsTNGXTango Therapeutics$4.69-7.1%$1.95$1.03▼$12.02$508.37M1.241.47 million shs2.44 million shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALTAltimmune+9.33%+30.95%+24.13%+20.78%+12.07%FSDDFFSD Pharma+5.64%+5.78%+68.53%+240.80%+6,100.08%RAPPRapport Therapeutics-7.93%-9.65%+11.51%+5.99%+1,113,999,900.00%TNGXTango Therapeutics+6.54%+43.87%+260.71%+158.97%-33.64%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALTAltimmune2.7647 of 5 stars3.52.00.00.02.23.30.6FSDDFFSD PharmaN/AN/AN/AN/AN/AN/AN/AN/ARAPPRapport Therapeutics1.9591 of 5 stars3.50.00.00.03.10.00.6TNGXTango Therapeutics2.1302 of 5 stars3.51.00.00.04.01.70.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALTAltimmune 3.00Buy$20.20191.91% UpsideFSDDFFSD Pharma 0.00N/AN/AN/ARAPPRapport Therapeutics 3.00Buy$32.67191.93% UpsideTNGXTango Therapeutics 3.00Buy$12.20160.13% UpsideCurrent Analyst Ratings BreakdownLatest FSDDF, RAPP, TNGX, and ALT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/14/2025TNGXTango TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$13.00 ➝ $13.004/8/2025RAPPRapport TherapeuticsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageMarket Outperform$28.004/8/2025RAPPRapport TherapeuticsCitizens JmpSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageMkt Outperform4/3/2025ALTAltimmuneHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$12.00 ➝ $12.003/18/2025ALTAltimmuneHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$12.00 ➝ $12.003/14/2025ALTAltimmuneWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Perform(Data available from 6/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALTAltimmune$20K28,063.02N/AN/A$2.75 per share2.52FSDDFFSD Pharma$70K2,057.43N/AN/AN/A∞RAPPRapport TherapeuticsN/AN/AN/AN/AN/AN/ATNGXTango Therapeutics$40.99M12.40N/AN/A$2.48 per share1.89Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALTAltimmune-$88.45M-$1.26N/AN/AN/A-199,076.92%-55.81%-50.60%8/6/2025 (Estimated)FSDDFFSD Pharma-$17.52MN/A0.00∞N/AN/AN/AN/AN/ARAPPRapport Therapeutics-$34.79M-$3.45N/AN/AN/AN/AN/AN/A8/14/2025 (Estimated)TNGXTango Therapeutics-$101.74M-$1.22N/AN/AN/A-284.42%-49.64%-32.00%8/6/2025 (Estimated)Latest FSDDF, RAPP, TNGX, and ALT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025ALTAltimmune-$0.35-$0.26+$0.09-$0.26$0.00 million$0.01 million5/12/2025Q1 2025TNGXTango Therapeutics-$0.34-$0.36-$0.02-$0.36$6.73 million$5.39 million5/8/2025Q1 2025RAPPRapport Therapeutics-$0.77-$0.68+$0.09-$0.68N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALTAltimmuneN/AN/AN/AN/AN/AFSDDFFSD PharmaN/AN/AN/AN/AN/ARAPPRapport TherapeuticsN/AN/AN/AN/AN/ATNGXTango TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALTAltimmuneN/A16.8716.87FSDDFFSD PharmaN/A1.811.60RAPPRapport TherapeuticsN/A45.9145.91TNGXTango TherapeuticsN/A8.008.00Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALTAltimmune78.05%FSDDFFSD Pharma0.43%RAPPRapport TherapeuticsN/ATNGXTango Therapeutics78.99%Insider OwnershipCompanyInsider OwnershipALTAltimmune4.10%FSDDFFSD PharmaN/ARAPPRapport TherapeuticsN/ATNGXTango Therapeutics6.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALTAltimmune5081.11 million68.21 millionOptionableFSDDFFSD Pharma107.58 millionN/ANot OptionableRAPPRapport TherapeuticsN/A36.50 millionN/AN/ATNGXTango Therapeutics90108.39 million100.65 millionOptionableFSDDF, RAPP, TNGX, and ALT HeadlinesRecent News About These CompaniesTango Therapeutics (NASDAQ:TNGX) Shares Down 7.4% - Here's What HappenedJune 13 at 3:17 PM | marketbeat.comEquities Analysts Offer Predictions for TNGX FY2026 EarningsJune 13 at 2:57 AM | americanbankingnews.comTango Therapeutics (NASDAQ:TNGX) Shares Gap Down - Time to Sell?June 12 at 3:47 PM | marketbeat.comB. Riley Expects Higher Earnings for Tango TherapeuticsJune 12 at 8:24 AM | marketbeat.comBrokers Offer Predictions for TNGX Q2 EarningsJune 12 at 1:19 AM | americanbankingnews.comCantor Fitzgerald Predicts TNGX FY2026 EarningsJune 11 at 8:45 AM | marketbeat.comQ2 Earnings Forecast for TNGX Issued By B. RileyJune 11 at 8:06 AM | marketbeat.comTango Therapeutics (NASDAQ:TNGX) Trading Up 11.8% - Should You Buy?June 10 at 3:48 PM | marketbeat.comTango Therapeutics, Inc. (NASDAQ:TNGX) Stock Holdings Increased by Bank of America Corp DEJune 9, 2025 | marketbeat.comMillennium Management LLC Invests $771,000 in Tango Therapeutics, Inc. (NASDAQ:TNGX)June 7, 2025 | marketbeat.comTango Therapeutics: PRMT5 Data Readout Due In 2025 Is CriticalJune 6, 2025 | seekingalpha.comAnalysts Set Tango Therapeutics, Inc. (NASDAQ:TNGX) Target Price at $12.20June 6, 2025 | americanbankingnews.comTango Therapeutics, Inc. (NASDAQ:TNGX) Given Consensus Recommendation of "Buy" by AnalystsJune 3, 2025 | marketbeat.comWoodline Partners LP Takes Position in Tango Therapeutics, Inc. (NASDAQ:TNGX)May 28, 2025 | marketbeat.comTango Therapeutics to Participate in the 46th Annual Goldman Sachs Global Healthcare ConferenceMay 27, 2025 | finance.yahoo.comTango Therapeutics to Participate in the 46th Annual Goldman Sachs Global Healthcare ConferenceMay 27, 2025 | globenewswire.comTango Therapeutics starts trial for brain cancer drugMay 23, 2025 | uk.investing.comTango Therapeutics Announces First Patient Dosed in TNG456 Phase 1/2 Trial in Patients With MTAP-deleted Glioblastomas and Other Solid TumorsMay 21, 2025 | globenewswire.com517,426 Shares in Tango Therapeutics, Inc. (NASDAQ:TNGX) Acquired by Jacobs Levy Equity Management Inc.May 19, 2025 | marketbeat.comQ2 EPS Estimate for Tango Therapeutics Increased by AnalystMay 17, 2025 | marketbeat.comDimensional Fund Advisors LP Purchases 302,087 Shares of Tango Therapeutics, Inc. (NASDAQ:TNGX)May 17, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeFSDDF, RAPP, TNGX, and ALT Company DescriptionsAltimmune NASDAQ:ALT$6.92 -0.23 (-3.22%) Closing price 04:00 PM EasternExtended Trading$6.92 +0.00 (+0.06%) As of 04:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.FSD Pharma OTCMKTS:FSDDF$19.00 +3.63 (+23.62%) As of 06/12/2025FSD Pharma, Inc. is a specialty biotech pharmaceutical research and development company. It focuses on developing over time a robust pipeline of FDA-approved synthetic compounds targeting the endocannabinoid system of the human body to treat certain diseases of the central nervous system and autoimmune disorders of the skin, GI tract, and the musculoskeletal system. The company was founded by Thomas Fairfull, Zeeshan Saeed and Anthony J. Durkacz in 1994 and is headquartered in Cobourg, Canada.Rapport Therapeutics NASDAQ:RAPP$11.19 +0.05 (+0.45%) Closing price 04:00 PM EasternExtended Trading$12.34 +1.16 (+10.32%) As of 04:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Rapport Therapeutics Inc. is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc. is based in BOSTON.Tango Therapeutics NASDAQ:TNGX$4.69 -0.36 (-7.13%) Closing price 04:00 PM EasternExtended Trading$4.68 -0.01 (-0.11%) As of 04:28 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company develops TNG462, an oral small molecule methylthioadenosine-cooperative inhibitor for the treatment for cancers with methylthioadenosine phosphorylase deletions; TNG260, a co-repressor of repressor element-1 silencing transcription -selective inhibitor; TNG348, an ubiquitin-specific protease 1 inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. It has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. Tango Therapeutics, Inc. was founded in 2017 and is headquartered in Boston, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Super Micro Computer Stock: 2 Levels Smart Money Is Watching Intel's Price Spikes: Noise, or the First Notes of a Turnaround? IBM Up 10 Days in a Row: What’s Driving the Winning Streak? SoFi Stock’s Next Test: Can It Justify Its Premium Valuation? Ignore the Noise—Samsara Stock Is Still a Strong Buy Fastenal Stock After Split: Poised for 5 More Years of Gains Analysts Love Lovesac, But Investors Should Be Cautious Oracle’s Cloud Boom Is Just Getting Started Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
